Canertinib (CI-1033) is an experimental drug candidate for the treatment of cancer.

[1][2] By 2015, Pfizer had discontinued development of the drug.

[3] Canertinib has been reported as a substrate for the transporter protein OATP1B3.

Interaction of canertinib with OATP1B3 may alter its hepatic disposition and can lead to transporter mediated drug-drug interactions.

This antineoplastic or immunomodulatory drug article is a stub.